Hip Replacement Liners for Osteoarthritis
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial examines the safety and effectiveness of the G7 Acetabular System for individuals needing a hip replacement due to conditions like osteoarthritis or rheumatoid arthritis. It tests different liners inside the hip joint to determine which performs best over the long term. Suitable candidates for this trial have osteoarthritis or similar conditions and are willing to attend follow-up visits. Participants must also understand and agree to the trial's terms. As an unphased study, this trial allows participants to contribute to valuable research that could enhance future hip replacement options.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that these hip replacement liners are safe for osteoarthritis patients?
Research has shown that the G7 Acetabular System is generally safe and effective for hip replacements. One study found that the G7 modular dual mobility cup is a safe choice without specific risks related to the implant. Patients using the G7 system can expect good safety outcomes.
For the liners used with the G7 system, both the Vivacit-E and Longevity liners have demonstrated positive safety records. The Vivacit-E liner, for example, wears down less than traditional materials, potentially leading to fewer problems over time. Studies have confirmed that these materials are as safe and effective as other similar products available.
Overall, evidence suggests that the G7 Acetabular System and its liners are a well-tolerated option for hip replacement surgery.12345Why are researchers excited about this trial?
The G7 Acetabular System is unique because it uses advanced liner materials like Vivacit-E and Longevity Highly Crosslinked Polyethylene. These materials are designed to improve wear resistance, potentially making hip replacements last longer compared to standard polyethylene liners. Researchers are excited because these liners could reduce the need for future surgeries, offering a more durable solution for patients with osteoarthritis.
What evidence suggests that the G7 Acetabular System is effective for osteoarthritis?
Research has shown that the G7 Acetabular System, which participants in this trial may receive, is safe and effective for hip replacements when used with either Vivacit-E or Longevity liners. One study found this system to be a reliable choice for patients, with no specific problems related to the implant. Vivacit-E liners contain Vitamin E, which helps reduce wear and tear by preventing damage from oxygen exposure. These liners are designed for strength, making them a good option for long-lasting hip replacements. Overall, evidence supports that this system can work well and last a long time for people needing hip joint replacements.12346
Who Is on the Research Team?
Hillary Overholser
Principal Investigator
Zimmer Biomet
Are You a Good Fit for This Trial?
This trial is for adults with full skeletal maturity who need hip replacement due to conditions like osteoarthritis or fractures. Candidates must be able to follow the study protocol and attend follow-up visits. Pregnant individuals, those with bone formation disorders, severe osteoporosis, infections that could affect the implant site, substance abuse issues, or unmanageable neuromuscular diseases cannot participate.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Implantation of the G7 Acetabular Shells with Vivacit-E or Longevity HXLPE liners in primary and revision total hip arthroplasty
Follow-up
Participants are monitored for safety and effectiveness after treatment, including assessment of implant survival and adverse events
Long-term follow-up
Continued monitoring of patient-reported outcomes and quality of life measures
What Are the Treatments Tested in This Trial?
Interventions
- G7 Acetabular System
- Vivacit-E and Longevity (HXLPE) Liners
G7 Acetabular System is already approved in European Union, United States for the following indications:
- Non-inflammatory degenerative joint disease
- Rheumatoid arthritis
- Correction of functional deformity
- Treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement
- Revision procedures where other treatment or devices have failed
- Non-inflammatory degenerative joint disease
- Rheumatoid arthritis
- Correction of functional deformity
- Treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement
- Revision procedures where other treatment or devices have failed
Find a Clinic Near You
Who Is Running the Clinical Trial?
Zimmer Biomet
Lead Sponsor
Dr. Nitin Goyal
Zimmer Biomet
Chief Medical Officer since 2021
MD from Harvard Medical School
Ivan Tornos
Zimmer Biomet
Chief Executive Officer since 2023
MBA from the University of Miami School of Business, BBA in Finance and International Marketing and Management from the University of Georgia Terry College of Business